Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 65 Results

Title
Intervention Indication Therapeutic Area Year Actions
Ivosidenib for previously treated advanced cholangiocarcinoma Ivosidenib (Tibsovo; AG-120) Cholangiocarcinoma Gastrointestinal Cancer 2022 View  |  Download
Intravenous Doxorubicin Nanoparticles for Advanced Hepatocellular Carcinoma Doxorubicin (Livatag; BA-003; Caelyx; Sarcodoxome; SP-1049C; Resmycin; JNS002; doxorubicin hydrochloride) Hepatocellular carcinoma (HCC) Gastrointestinal Cancer 2017 View  |  Download
Infigratinib for unresectable locally advanced or metastatic cholangiocarinoma with FGFR2 rearrangements – second line Infigratinib (BGJ398; BGJ-398; Truseltiq) Cholangiocarcinoma Gastrointestinal Cancer 2021 View  |  Download
Fruquintinib for treating refractory metastatic colorectal cancer Fruquintinib (Elunate; TAK113; HMPL013) Colorectal cancer Gastrointestinal Cancer , Oncology 2023 View  |  Download
Favezelimab-pembrolizumab for treating metastatic PD-L1 positive colorectal cancer Favezelimab-pembrolizumab Colorectal cancer Gastrointestinal Cancer , Oncology 2023 View  |  Download
Eryaspase in addition to chemotherapy for treating advanced or metastatic pancreatic cancer – second-line Eryaspase (Graspa; ERY001) , FOLFOX4 , Gemcitabine (Gemzar; gemcitabine hydrochloride) Pancreatic cancer Gastrointestinal Cancer 2020 View  |  Download
Encorafenib in combination with binimetinib and cetuximab for BRAF V600E mutant metastatic colorectal cancer Binimetinib (MEK162; MEK-162; ARRY-162) , Cetuximab (Erbitux; STI-001) , Encorafenib (LGX818) Colorectal cancer Gastrointestinal Cancer , Oncology 2019 View  |  Download
Durvalumab with transarterial chemoembolisation for hepatocellular carcinoma Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Transarterial Chemoembolisation (TACE) Hepatocellular carcinoma (HCC) Gastrointestinal Cancer 2022 View  |  Download
Durvalumab with fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy for neoadjuvant and adjuvant treatment of resectable gastric and gastro-oesophageal junction cancer 5-Fluorouracil , Docetaxel (Taxotere; docetaxel trihydrate; docetaxel anhydrous) , Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Leucovorin , Oxaliplatin Gastro-oesophageal junction cancer Gastrointestinal Cancer 2023 View  |  Download
Durvalumab with bevacizumab adjuvant therapy for treating newly diagnosed hepatocellular carcinoma at high risk of recurrence after curative therapy Bevacizumab (Avastin; R 435; RG 405; RG 435) , Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) Hepatocellular carcinoma (HCC) Gastrointestinal Cancer 2022 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications